Navigation Links
Study Reports Successful Cloning of Human Embryo Using Adult DNA

Key Step Toward Developing Embryonic Stem Cell Lines for Therapeutic


DURHAM, N.C., Jan. 17 /PRNewswire/ -- A California research team has become the first to report, and painstakingly document, the cloning of a human embryo using donated oocytes (egg cells) and DNA from the cells of an adult donor. The study was published online today by the journal "Stem Cells."

(Logo: )

The experiments, using a technique called somatic cell nuclear transfer (SCNT), provide key steps toward the development of patient-specific embryonic stem cells for use in developing new treatments for conditions such as Alzheimer's disease, Parkinson's disease, and spinal cord injury, among others. The lead author was Andrew J. French, Ph.D., of Stemagen Corp., a private company headquartered in La Jolla, Calif.

In the experiments, the researchers removed the nuclei of mature oocytes from healthy young women who had previously donated eggs for successful infertility treatments. The SCNT technique was then used to insert DNA from an adult male donor into the oocytes. The DNA was derived from a type of cell called fibroblasts, obtained from skin biopsies.

Subsequently, several of the reconstructed oocytes continued to develop as normal embryos, to the blastocyst stage. Extensive and carefully documented genetic tests were performed to confirm the genetic identity of the cloned embryos. In three embryos, tests showed the same DNA as the male fibroblast donor.

In one of the three cases, additional tests showed that the embryo had another type of DNA, called mitochondrial DNA, from both the female oocyte donor and the male DNA donor.

Mitochondrial DNA testing is viewed as an essential proof of successful human cloning -- particularly after previous fabricated reports from a South Korean research group. Amidst this background of controversy, the researchers took extraordinary steps to ensure that their experiments were properly conducted and documented. These included approval by an independent review board and confirmation of the genetic results by an independent laboratory, among other steps.

The ability to generate stem cells using the patient's own DNA holds great promise for the treatment of currently incurable degenerative diseases, as well as for cell-based drug discovery. Previous studies reporting the development of cloned human embryos have used embryonic stem cells as the DNA donors.

"This study demonstrates, for the first time, that SCNT can be utilized to generate cloned human blastocysts using differentiated adult donor nuclei remodeled and reprogrammed by human oocytes," the researchers write. They believe that some key technical factors contributed to their successful results, including the use of freshly donated oocytes from successful egg donors.

While the study is an important step toward the development of stem cells for therapeutic cloning, much more research will be needed to confirm and extend the results. Dr. French comments, "The data we present are not in any way the final word on this topic, but, we anticipate, just one of many publications from a variety of researchers who will use a variety of methods to conduct and analyze similar experiments."

Dr. Miodrag Stojkovic, Co-Editor of "Stem Cells," comments: "These researchers have for the first time developed cloned embryos up to blastocyst stage using adult somatic [skin] cells as donor cells. This is a key advance in the development of patient-specific stem cell lines for therapeutic and drug development purposes. Although these results are preliminary since no stem cell lines have been derived from the cloned embryos, this may now be attempted."

The article, entitled "Development of Human Cloned Blastocysts Following Somatic Cell Nuclear Transfer (SCNT) with Adult Fibroblasts," is available online at:

About AlphaMed Press

AlphaMed Press publishes the internationally renowned journals, "Stem Cells" and "The Oncologist." "Stem Cells," now in its 26th year, is the oldest and one of the world's top-tier peer-reviewed monthly journals in the fast-paced area of stem cells and regenerative medicine. "The Oncologist," in its 13th year, is a premier peer-reviewed monthly journal dedicated to physicians entrusted with the care of cancer patients. View AlphaMed Press journals at

Contact: George Kendall: 919-680-0011,

SOURCE AlphaMed Press
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
2. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
3. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
4. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
5. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
6. Schering-Plough Reports Top-Line Results of the IDEAL Study
7. Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of DG051 for the Prevention of Heart Attack
8. Knee Pain? An Exclusive Study Engineers Cartilage to Match Patients Own Tissue
9. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
10. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
11. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
Post Your Comments:
(Date:10/12/2015)... 12, 2015 Device usage in healthcare continues ... integrate these devices into existing clinical workflow. In response, ... and mobility solutions, has launched the SV10 series of ... a wide array of laptops and tablets. In addition, ... exclusively for Microsoft Surface and is compatible with all ...
(Date:10/12/2015)... October 12, 2015 ... to grow at 7.2% CAGR, microscopy market ... rising focus on nanotechnology, technological advancements, and ... report available with ... . --> Complete report on ...
(Date:10/12/2015)... Oct. 12, 2015 Indivior PLC (LON: INDV) today ... Delaware granted the Company,s motion to ... New Drug Application (ANDA) No. 205299 to market a generic ... naloxone) Sublingual Film (CIII) in the United States ... Since August 2013, Indivior has received Paragraph IV certifications from ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... ... on being awarded a contract with the U.S. Biomedical Advanced Research and Development ... development and procurement of its ReCell® Autologous Cell Harvesting Device under a U.S. ...
(Date:10/12/2015)... ... October 12, 2015 , ... The translation for ARIS® 7.x ... migration of complete ARIS installations into the Microsoft world. The ARIS models will be ... Visio® is very familiar for both IT and Office users it is acknowledged as ...
(Date:10/12/2015)... ... October 12, 2015 , ... The ... to 8:00 pm at the Sheraton Philadelphia Hotel, 3549 Chestnut Street, Philadelphia, PA ... attending from across the country. All specialties will be represented. Attendees will enjoy ...
(Date:10/12/2015)... Greifensee, Switzerland (PRWEB) , ... October 12, 2015 ... ... of new product upgrades designed to streamline laboratory processes. In addition, METTLER TOLEDO ... a free Lean Lab Checklist to help improve productivity through the ...
(Date:10/12/2015)... ... ... On Sept. 26, the team at Dynamic Fitness joined supporters from 58 ... Houston Zoo during September's Childhood Cancer Awareness Month. The Walk/Run helped to raise funds ... up with the idea to involve his team with the walk in an effort ...
Breaking Medicine News(10 mins):